PL2163247T3 - Zastosowanie naringeniny i naringiny jako inhibitorów dla ścieżki sygnałowej transformującego czynnika wzrostu BETA1 - Google Patents

Zastosowanie naringeniny i naringiny jako inhibitorów dla ścieżki sygnałowej transformującego czynnika wzrostu BETA1

Info

Publication number
PL2163247T3
PL2163247T3 PL08772950T PL08772950T PL2163247T3 PL 2163247 T3 PL2163247 T3 PL 2163247T3 PL 08772950 T PL08772950 T PL 08772950T PL 08772950 T PL08772950 T PL 08772950T PL 2163247 T3 PL2163247 T3 PL 2163247T3
Authority
PL
Poland
Prior art keywords
naringin
naringenin
inhibitors
growth factor
signaling pathway
Prior art date
Application number
PL08772950T
Other languages
English (en)
Inventor
Wei Liang
Gangjun Du
Hongyan Zhang
Lingtao Jin
Heping Lv
Wei Wang
Jinping Liu
Guohua Jiao
Original Assignee
The Inst Of Biophysics Chinese Academy Of Sciences
Henan Topfond Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Inst Of Biophysics Chinese Academy Of Sciences, Henan Topfond Pharmaceutical Co Ltd filed Critical The Inst Of Biophysics Chinese Academy Of Sciences
Publication of PL2163247T3 publication Critical patent/PL2163247T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08772950T 2007-06-13 2008-06-11 Zastosowanie naringeniny i naringiny jako inhibitorów dla ścieżki sygnałowej transformującego czynnika wzrostu BETA1 PL2163247T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2007101188713A CN101322700B (zh) 2007-06-13 2007-06-13 柚皮素和柚皮苷作为转化生长因子-β1信号通路抑制剂在制备药物中的应用
PCT/CN2008/001129 WO2008151519A1 (fr) 2007-06-13 2008-06-11 UTILISATION DE NARINGÉNINE ET DE NARINGINE EN TANT QU'INHIBITEURS POUR LA TRANSFORMATION D'UNE VOIE DE SIGNALISATION DU FACTEUR DE CROISSANCE β1
EP08772950.5A EP2163247B1 (en) 2007-06-13 2008-06-11 USE OF NARINGENIN AND NARINGIN AS INHIBITORS FOR TRANSFORMING GROWTH FACTOR-beta1 SIGNALING PATHWAY

Publications (1)

Publication Number Publication Date
PL2163247T3 true PL2163247T3 (pl) 2015-02-27

Family

ID=40129230

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08772950T PL2163247T3 (pl) 2007-06-13 2008-06-11 Zastosowanie naringeniny i naringiny jako inhibitorów dla ścieżki sygnałowej transformującego czynnika wzrostu BETA1

Country Status (7)

Country Link
EP (1) EP2163247B1 (pl)
JP (1) JP5484320B2 (pl)
CN (1) CN101322700B (pl)
DK (1) DK2163247T3 (pl)
ES (1) ES2519040T3 (pl)
PL (1) PL2163247T3 (pl)
WO (1) WO2008151519A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102302483A (zh) * 2011-07-08 2012-01-04 中国科学院生物物理研究所 黄酮类小分子药物在抗炎及相关疾病中的应用
WO2014063660A1 (en) * 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of fibrosis
JP2016027015A (ja) * 2014-06-24 2016-02-18 花王株式会社 Smad3阻害剤
CN104940932A (zh) 2015-07-10 2015-09-30 中国科学院生物物理研究所 柚皮素和柚皮苷在肿瘤放射治疗中的应用
CN108057034A (zh) * 2016-11-09 2018-05-22 香港中文大学 柚皮素和积雪草酸组合治疗癌症
CN106880685B (zh) * 2017-02-21 2020-07-17 新乡医学院第一附属医院 一种治疗肝纤维化的复方制剂及其制备方法
WO2019200585A1 (en) * 2018-04-19 2019-10-24 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of cancers
CN109771412A (zh) * 2018-12-29 2019-05-21 遵义医学院 减轻球囊损伤后血管再狭窄的药物及大鼠模型构建方法
EP4146194A1 (en) * 2020-05-08 2023-03-15 Gretals Australia Pty Ltd Compositions and methods for the prophylaxis and treatment of fibrotic and inflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2633182B1 (fr) * 1988-06-23 1993-07-23 Beljanski Mirko Composition pharmaceutique anticancereuse et methode d'utilisation de l'invention
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
WO2006128169A2 (en) * 2005-05-26 2006-11-30 The Ohio State University Research Foundation Inhibition of monocyte survival, differentiation, or proliferation
CN1813779A (zh) * 2005-11-23 2006-08-09 中山大学 柚皮苷在制备防治流感药物中的应用

Also Published As

Publication number Publication date
ES2519040T3 (es) 2014-11-06
EP2163247A4 (en) 2010-07-14
WO2008151519A1 (fr) 2008-12-18
EP2163247A1 (en) 2010-03-17
EP2163247B1 (en) 2014-08-20
JP5484320B2 (ja) 2014-05-07
JP2010529049A (ja) 2010-08-26
CN101322700A (zh) 2008-12-17
DK2163247T3 (da) 2014-11-10
CN101322700B (zh) 2010-08-25

Similar Documents

Publication Publication Date Title
EP2163247A4 (en) USE OF NARINGENIN AND NARINGIN AS INHIBITORS FOR THE CONVERSION OF THE GROWTH FACTOR BETA1 SIGNALS METABOLISM
HUS2200052I1 (hu) Imidazotriazinok és imidazopirimidinek mint kinázgátlók
HK1254895A1 (zh) 苄基苯衍生物及使用方法
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
HK1162352A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2311002A4 (en) SYSTEMS AND METHOD FOR THE VISUAL PRESENTATION OF OFFERS
EP2114983A4 (en) TYROSINE KINASE ACTIVATED AXL RECEPTOR INHIBITORS AND METHODS OF MAKING AND USING THE SAME
ZA200905626B (en) Adjuvants and methods of using them
EP2046374A4 (en) COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS
EP2376014A4 (en) OBERKIEFERKNOCHEN CUTTING AND INJECTION SYSTEM AND USE METHOD THEREFOR
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
EP2451376A4 (en) METHOD AND SYSTEMS FOR ADJUSTING THE PH VALUE OF MEDICAL BUFFER SOLUTIONS
ZA200907337B (en) Methods of increasing plant growth
AP2008004406A0 (en) Methods of managing timberland
IL200387A0 (en) Heterocylic compounds, compositions comprising them and methods of their use
ZA200808245B (en) Compositions and methods for inducing bone growth and inhibiting bone loss
EP2459187A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING HAIR GROWTH
ZA201102547B (en) Compositions and methods for the rapid growth and detection of microorganisms
IL205821A0 (en) Method and compositions for cutaneous immunisation
AP2784A (en) Methods of managing timberland
EP2252939A4 (en) METHOD AND SYSTEMS FOR SYNCHRONIZING MULTIPLE APPLICATIONS
WO2008153938A3 (en) Epigallocatechin-3-gallate crystal compositions
EP1999248A4 (en) DEVICES AND METHODS FOR ISOLATION AND CULTURE OF MICROORGANISMS
EP2280698A4 (en) PROCESS FOR INHIBITING BACTERIAL GROWTH